
The pain of acute gout is unbearable
Acute gout is an immune response induced by the rapid change in urate concentration in the joint cavity, which leads to the secretion of inflammatory factors after phagocytosis of urate microcrystals. Generally, the onset is rapid, the pain is unbearable, and the joints and surrounding tissues are affected by redness, swelling, warmth, pain and other symptoms.
At present, the first-line medication of acute gout is Colchicine, NSAID, and COX-2 inhibitor, but these drugs have many toxic and side effects. Due to the high frequency of acute gout in gout patients, long-term medication is required. The toxic and side effects of first-line medications such as colchicine often limit their use in the field of gout. Patients with acute gout would be eager for the emergence of new drugs with equivalent efficacy and low toxicity.

Atom Therapeutics' ABP-745 has exhibited higher safety and tolerability advantages than current drugs on the market
ABP-745 has shown significant pharmacodynamic activity in an animal model of acute gout, significantly reducing pain in rats, improving their gait, and reducing swelling of ankle joints and the level of inflammatory factors. In addition, the nonclinical and Phase 1 clinical data showed that ABP-745 exhibited higher safety and tolerability compared to existing drugs on the market. Based on its positive inhibitory effects on various inflammatory factors, ABP-745 also is in development for other related indications.